---
title: PopPK Modeling of Rivoceranib in Healthy Subjects and Cancer Patients
description: This poster focuses on the pharmacokinetic study of rivoceranib in healthy subjects and patients with various cancers.
image: https://www.amadorbioscience.com/hubfs/640%20(1).webp
---

![amador bioscience-png](https://www.amadorbioscience.com/hs-fs/hubfs/Web/logo/amador%20bioscience-png.png?width=166&height=64&name=amador%20bioscience-png.png)

- [Bioanalysis and Biomarker Services](https://www.amadorbioscience.com/bioanalysis-lab-solutions)
- [Clinical Pharmacology](https://www.amadorbioscience.com/clinical-pharmacology-services)
- [Regulatory Affairs](https://www.amadorbioscience.com/regulatory-affairs)
- [Clinical Research Services](https://www.amadorbioscience.com/clinical-research-services)
- [About Us](https://www.amadorbioscience.com/about-amador-bioscience) 
    - [About Amador](https://www.amadorbioscience.com/about-amador-bioscience)

- [News](https://www.amadorbioscience.com/news)
- [Resources](https://www.amadorbioscience.com/blog)
- [Amador China](https://www.amadorbio.cn)

# PopPK Modeling of Rivoceranib in Healthy Subjects and Cancer Patients

This poster focuses on the pharmacokinetic study of rivoceranib in healthy subjects and patients with various cancers. 

![PopPK Modeling of Rivoceranib in Healthy Subjects and Cancer Patients](https://www.amadorbioscience.com/hubfs/640%20(1).webp)\\

From left to right, Bing Wang, CEO of AmadorBio; Kevin Shen, Head of Clinical Pharmacology, Hengrui; Nassim Djebli, Executive Director (Head of Pharmacometrics), Hengrui

- Recipients of “Top Poster Ribbon” in “Recognition of high-quality abstract”

This poster focuses on the pharmacokinetic study of Rivoceranib in both healthy subjects and patients with various types of cancers. By collecting and analyzing data from different populations (e.g. cancer patients, healthy individuals, etc.), a kinetic model of drug absorption, distribution, metabolism and excretion in the human body was developed. The study revealed that different disease types can impact the pharmacokinetic properties of drugs. For instance, drug clearance is reduced in liver cancer patients, while bioavailability is decreased in gastric cancer patients. These findings are crucial for the development of tailored treatment plans.

 

![Rivoceranib_PPK_Poster_ASCPT2024_FINAL_logos 拷贝](https://www.amadorbioscience.com/hs-fs/hubfs/Rivoceranib_PPK_Poster_ASCPT2024_FINAL_logos%20%E6%8B%B7%E8%B4%9D.jpg?width=9999&height=5624&name=Rivoceranib_PPK_Poster_ASCPT2024_FINAL_logos%20%E6%8B%B7%E8%B4%9D.jpg)

 

## Want to learn more?

[![Talk to an Expert](https://no-cache.hubspot.com/cta/default/22807122/87da9502-b1f2-408c-afe6-0276c6108ea9.png)](https://cta-redirect.hubspot.com/cta/redirect/22807122/87da9502-b1f2-408c-afe6-0276c6108ea9)

![未标题-1](https://www.amadorbioscience.com/hs-fs/hubfs/%E6%9C%AA%E6%A0%87%E9%A2%98-1.png?width=210&height=80&name=%E6%9C%AA%E6%A0%87%E9%A2%98-1.png)

- Contact 
    - [Email Us](mailto:CBS_contact@crystalpharmatech.com)
    - +1-609-604-8303
    - [Contact Us](https://www.amadorbioscience.com/contact-amador)
- Our Services 
    - [Bioanalysis and Biomarker Services](https://www.amadorbioscience.com/bioanalysis-lab-solutions)
    - [Clinical Pharmacology](https://www.amadorbioscience.com/clinical-pharmacology-services)
    - [Regulatory Affairs](https://www.amadorbioscience.com/regulatory-affairs)
    - [Clinical Research Services](https://www.amadorbioscience.com/clinical-research-services)
- Information 
    - [About Us](https://www.amadorbioscience.com/about-amador-bioscience)
    - [Careers](https://www.crystalpharmatech.com/careers/)
    - [Events](https://www.crystalpharmatech.com/events/)
    - [News](https://www.amadorbioscience.com/news)

- [Privacy Policy](https://www.amadorbioscience.com/privacy-policy)
- [Terms & Conditions](https://www.amadorbioscience.com/terms-conditions)

By signing up, you agree to the [Privacy Policy](https://www.amadorbioscience.com/privacy-policy).

Copyright © 2026 Amador Bioscience, All rights reserved

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Amador Bioscience",
    "url" : "https://www.amadorbioscience.com/blog/author/amador-bioscience"
  },
  "dateModified" : "2024-07-10T01:55:03.339Z",
  "datePublished" : "2024-04-02T03:26:34.000Z",
  "headline" : "PopPK Modeling of Rivoceranib in Healthy Subjects and Cancer Patients",
  "image" : [ "https://www.amadorbioscience.com/hubfs/640%20(1).webp" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.amadorbioscience.com/blog/poppk-modeling-of-rivoceranib-in-healthy-subjects-and-cancer-patients",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.amadorbioscience.com/hubfs/Horizontal%20Amador%20logo-EN%20(1).png"
    },
    "name" : "Amador Bioscience"
  }
}
```